PREP

What can we help you find?
[[thumbnail_alt_text]]
Researchers investigate whether on-demand pre-exposure prophylaxis was similarly effective among individuals with lower exposure to HIV risk. 
[[thumbnail_alt_text]]
A study sought to determine how HIV avoids the antiviral protein, zinc-finger antiviral protein.
[[thumbnail_alt_text]]
A study used sequence-based methods to identify specific virus characteristics that may help determine efficacy of antibody therapies in HIV.
 
[[thumbnail_alt_text]]
The CDC reported progress with the current status of the 3 strategies within the national initiative, Ending the HIV Epidemic: A Plan for America.
[[thumbnail_alt_text]]
A report suggests that addressing financial barriers to antiretroviral therapy adherence may improve levels of viral suppression.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
[[thumbnail_alt_text]]
The FDA has approved Descovy (emtricitabine 200-mg and tenofovir alafenamide 25-mg tablets) for HIV-1 pre-exposure prophylaxis (PrEP).
[[thumbnail_alt_text]]
National Institutes of Health experts discuss optimization of existing strategies for HIV treatment and prevention, as well as the development of new approaches.
 
[[thumbnail_alt_text]]
California has passed SB 159, becoming the first state allowing pharmacists to dispense HIV prevention pills to patients without a doctor’s prescription. Supporters say the legislation will greatly reduce the spread of infection.1

 
[[thumbnail_alt_text]]
TIN Rx is aiming to serve the most vulnerable populations, including LGBTQ patients, homeless patients, and others who may typically face stigma in pharmacies.
 
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.